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Abstract: In the last decades, in addition to conventional imaging techniques and magnetic 
resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (FDG PET/CT) has been shown to be relevant in the detection and management 
of breast cancer recurrence in doubtful cases in selected groups of patients. While there are 
no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival 
benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse 
when traditional imaging methods are equivocal or conflicting and for identifying or confirming 
isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals 
with the potential role of FDG PET in these clinical settings by comparing its accuracy and 
impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium 
fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of 
patients’ satisfaction and acceptability are also discussed.
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Introduction to the types and rates of breast cancer 
recurrence
Breast cancer is the most common type of cancer and the second leading cause of cancer-
related death among women. It affects more than 1 million women worldwide.1 Available 
data show an estimated incidence at 1.67 million of new cases in the world by year;2 
moreover, approximatively 30% of patients relapses within 15 years after initial treatment.1
Breast cancer is a highly heterogeneous disease, which is currently classified into 
several different subtypes; this information is useful for predicting response to treat-
ment.3 The most relevant prognostic factors in the prediction of treatment outcome, 
recurrence-free survival and disease-specific survival are: tumor nodes metastasis 
(TNM) stage, histological evaluation, gene expression profiling and age.4,5
From the staging point-of-view, survival for breast cancer is strongly related to 
the baseline TNM evaluation (Table 1 for details on TNM staging in breast cancer 
patients). In fact, 1-year survival for breast cancer is highest for patients diagnosed at 
stage I and lowest for those diagnosed at stage IV.1
Other than the TNM staging, the tumor is classified on morphological bases. The 
most common type of breast cancer is invasive ductal carcinoma not otherwise specified 
(ductal NOS; 70% of breast cancer cases). Ductal NOS corresponds to a heterogeneous 
group of tumors that fail to exhibit sufficient characteristics to achieve classification 
as a specific histological type, such as lobular or tubular carcinoma.6 The second most 
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frequent type of breast cancer is the invasive lobular carci-
noma (ILC). It represents 5%–15% of invasive breast tumors 
and appears as an invasive carcinoma, usually associated with 
lobular carcinoma in situ. It is composed of non-cohesive 
cells, individually dispersed or arranged in single-file linear 
pattern in a fibrous stroma.6 Finally, medullary carcinoma 
represents between 1% and 7% of breast cancer. It is a well-
circumscribed carcinoma composed of poorly differentiated 
cells arranged in large sheets, with no glandular structures, 
scant stroma and a prominent lymphoplasmacytic infiltrate.6
With respect to gene expression profiling, the St. Gallen 
International Expert Consensus proposed a new intrinsic 
biological classification system, based on the expression of 
the estrogen receptor (ER), progesterone receptor, human 
epidermal growth factor receptor 2 (HER2) and Ki-67. The 
classification system categorizes invasive breast carcinomas 
into the following 5 distinct molecular subtypes: luminal A, 
luminal B (HER2-), luminal B (HER2+), HER2 and triple 
negative/basal-like subtypes. These different subtypes are 
managed with different therapeutic approaches and are linked 
with different recurrence risk as well as with distinct prognos-
tic stratification.7 The luminal-like tumors express hormone 
receptors (HRs), with expression profiles reminiscent of the 
luminal epithelial component of the breast.8 They are the most 
common subtype among breast cancers, with luminal A being 
the majority. The luminal-like tumors carry a good prognosis 
although luminal B tumors have a significantly worse prog-
nosis and high recurrence scores compared to the luminal A 
subtype. Luminal tumors respond well to hormone therapy, but 
poorly to conventional chemotherapy. ER-positive tumors are 
associated with a higher recurrence rate but are less frequently 
fatal.9 Conversely, over-expression of HER2 predicts a poor 
prognosis; these tumors are more sensitive to cytotoxic therapy. 
The triple-negative/basal subtypes are associated with young 
patient age and present an aggressive clinical course. These 
tumors are also associated with a lower disease-specific sur-
vival and higher risk of local and regional relapse.10
Recurrence can occur as: 1) local recurrence when the 
relapsing lesion is in the same area of the breast (ipsilateral) 
or in the mastectomy scar; 2) regional recurrence (lymph 
nodes in the ipsilateral axilla); 3) distant recurrence (more 
frequently mediastinal lymph nodes, bones, lungs, liver and 
brain.). Two-thirds of breast recurrences are local and occur 
more frequently within 5 years of the initial diagnosis.5
Finally, age is also a relevant prognostic factor as younger 
age is related to a greater chance of recurrence.5
Summary of current diagnostic 
methods
Local and regional recurrence
The most common site of local recurrence after breast con-
serving surgery and adjunct whole-breast irradiation, is the 
site of the primary breast cancer, representing 88% of local 
recurrences. Other manifestations of local recurrence are 
found in the same breast, in a different breast quadrant or as 
radiation-induced carcinoma within the treatment  portal.11 








T4a Extension to chest wall (does not include 
pectoralis muscle invasion)





N0 No lymph node metastasis
N1a 1–3 axillary nodes
N1b Internal mammary nodes with metastasis by 
sentinel node biopsy but not clinically detected
N1c a+b
N2a 4–9 axillary nodes
N2b Internal mammary nodes, clinically detected, 
without axillary nodes
N3a >10 axillary nodes or infraclavicular
N3b Internal mammary nodes, clinically detected, 
with axillary nodes or >3 axillary nodes 
and internal axillary mammary nodes with 
microscopic metastasis by sentinel node biopsy 
but not clinically detected
N3c Supraclavicular
M Metastasis
M0 No distant metastasis
Ml Distant metastasis
Stage T N M
Breast cancer staging
0 Tis N0 M0
IA T1 N0 M0
IB T0/T1 N1 micro M0
IIA T0/T1 N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0/T1/T2 N2 M0
T3 N1/N2 M0
IIIB T4 N0/N1/N2 M0
IIIC Any T N3 M0
IV Any T Any N Ml
Abbreviations: pT, tumor size; TNM, tumor, node, metastasis.




Breast cancer restaging and 18F-FDG PET/CT
Early detection and treatment of isolated locoregional recur-
rences before symptomatic onset may have a beneficial 
effect on the prognosis, by improving local treatment fea-
sibility rate and by avoiding the situation of uncontrollable 
locoregional disease.12–14 According to these data, National 
Comprehensive Cancer Network (NCCN) and American 
Society of Clinical Oncology guidelines recommend routine 
follow-up visits, including clinical breast examination and 
mammography (Mx) for at least 5 years. In particular, clinical 
breast examination is recommended every 3 months and a 
mammogram every 6 months for the first 2 years, followed by 
a mammogram once a year with clinical breast examination 
twice a year for the next 3 years.12,15 Current strategies for 
the local breast cancer recurrence detection mainly include 
Mx, ultrasonography (US) and magnetic resonance imaging 
(MRI).16 Digital tomosynthesis is gaining an emerging role 
in the evaluation of radiographically dense breasts.17
Regular Mx is recommended in the follow-up program 
for all breast cancer patients as up to one-third of local 
recurrences are detected by Mx alone (more likely in the 
conserved breast). The recurrence usually presents similar 
mammographic features with respect to the original tumor.12,18 
Advantages of Mx comprise wide availability, reduced cost 
and a high diagnostic accuracy in reference centers. This 
satisfactory performance reflects an established approach and 
a consolidated standardization, making Mx a non-operator-
dependent technique. However, the sensitivity of Mx in the 
detection of local recurrences ranges from 55% to 68%, 
being influenced by an insufficient morphological distinc-
tion between therapy-induced edema and lymphangiosis 
carcinomatosa or between radially striated scar tissue and 
tumor recurrence. In fact, the treated breast may be more 
difficult to position because of surgical deformities or may 
be relatively noncompressible because of pain or structural 
changes. Changes following breast-conserving surgery can 
include hematoma, seroma, fat tissue necrosis, scar tissue 
development and dystrophic calcifications. Radiotherapy-
induced alterations can include vascular dilatation, capil-
lary damage, microcirculatory changes and consequent 
edema. The summation of these changes complicates the 
interpretation of clinical examination and Mx due to focal 
thickening, decreased compressibility and increased density 
at the surgical site.19 In this scenario, US has high sensitivity 
if performed at regular intervals, because of the detection of 
hypoechoic nodules within fibrous hyperechoic tissue.12,19
Early detection of regional breast cancer recurrence in 
asymptomatic patients has a positive effect on survival but 
may be difficult for several reasons. First, there is no  reliable 
screening or diagnostic tool to evaluate the axillary and supra-
clavicular lymph node areas, which are useful predictors of 
concurrent or subsequent distant metastasis. Moreover, the 
false-negative rate of the axilla at physical examination is 
high, reaching up to 39%. Physical examination of regional 
lymph nodes is hindered by factors such as anatomic loca-
tion (beneath the clavicle or deep in subcutaneous fat tissue), 
scar tissue due to previous axillary lymph node dissection or 
radiation, obesity and small size of the recurrence. Since the 
false-negative rate of physical examination of the axilla is so 
high and the field of view of Mx does not include this entire 
area, US after breast cancer surgery is recommended, also in 
asymptomatic patients, in order to detect lymph node region 
recurrence.13,20 However, US sensitivity is user-dependent and 
may be diminished in the presence of small or noninvasive 
lesions, especially in fatty breasts.12,19
MRI may be superior to traditional imaging in diagnosis 
of recurrence in the presence of scar tissue when performed 
at least 12–18 months after breast conserving surgery and at 
greater intervals from radiotherapy.
Sensitivity levels of MRI for diagnosis of suspected breast 
cancer recurrence ranged from 75% to 100% while specificity 
ranged from 66% to 100%. Sensitivity and specificity were 
consistently higher for MRI compared with Mx or ultrasound 
alone. MRI has shown an extremely high negative predictive 
value (98.8%) in the detection of breast cancer recurrence, 
including lesions not related to the surgical scar, thus allow-
ing avoidance of the need for further biopsy in the presence 
of negative MRI. Moreover, in published studies, MRI has 
been demonstrated to detect cancers in contralateral breasts 
that were overlooked by clinical examinations, Mx and 
sonography at the time of initial diagnosis in 3.1%–18.6% 
of patients.13,21–23 In summary, MRI has a sensitivity ranging 
from 75% to 100% for detecting suspected breast cancer 
recurrence in women previously treated for breast cancer 
with either breast conserving surgery and radiotherapy or 
mastectomy. Given its higher costs and lower availability, 
MRI cannot be recommended in the routine surveillance for 
breast cancer recurrence, but should be used in the case of 
suspected recurrence when clinical, mammographic and/or 
sonographic findings are inconclusive or other investigations 
have equivocal findings.19,23 Finally, MRI is particularly use-
ful for surveillance of young women due to its proven higher 
sensitivity compared with Mx, especially in dense breasts.24–28
Distant metastasis
Most frequently, metastases from breast cancer occur 
within the mediastinal lymph nodes (frequently f irst 





ipsilateral and then contralateral), bones, lungs, liver 
and brain. Different patients’ and tumor characteristics 
are related to different patterns of distant relapse: bone 
metastases are more likely to be diagnosed in patients 
with HR-positive disease, while lung and liver metastases 
are more common in patients with a more advanced stage 
at the time of diagnosis; finally, brain metastases were 
mostly observed in patients with HR-negative disease.29,30 
Currently, restaging of breast cancer patients is predomi-
nately based on physical examination, blood parameters, 
computed tomography (CT), MRI, US and X-rays (XR) as 
well as bone scintigraphy. Distant metastases are revealed 
in 16%–20% of patients.
CT is able to assess the most frequent sites of metastases 
and is widely available. CT is the primary modality used 
to detect intrathoracic lymph node enlargement (whenever 
the short-axis diameter of a lymph node exceeds 1 cm).31 
Skeletal tissue is the second most common (30%–85%) site 
of distant localization and the first site of metastasis in up to 
50% of all stage IV breast cancer. Breast cancer metastasis in 
the bone alters osteoclast and osteoblast function, resulting 
in bone destruction, which can be detected by CT.16,32,33 On 
CT, skeletal metastasis appears as lytic, sclerotic, or mixed 
lesions that may be complicated by pathologic fracture 
or spinal cord compression. Sagittal CT reformations are 
better than XR and bone scintigraphy (BS) for detecting 
vertebral body compression fractures and epidural exten-
sion of metastasis.
BS remains the most suitable technique for whole-body 
screening of bone metastasis due to its low cost and high 
availability. However, it often requires integration with 
other modalities (XR, CT or MRI).34,35 BS sensitivity ranges 
from 62% to 100% and its specificity is between 78% and 
100%.35 BS is more sensitive than CT and XR for the early 
detection of skeletal metastasis, but it has lower specificity 
and higher false-positive rates than XR because the uptake 
of radionuclide in BS reflects the metabolic reaction of 
bone caused by benign alterations (e.g., fracture, arthri-
tis, or infection).36 Moreover, a significant proportion of 
breast cancer bone metastases are osteolytic. In the case 
of rapid osteolytic growth, when bone turnover is slow, 
or when the site is avascular (photon-deficient lesions; 
“cold spots”), bone scans are often falsely negative.16 In 
summary, although planar bone scanning has recognized 
limitations, in particular poor specificity in staging and 
response assessment, it continues to be the mainstay of 
skeletal staging in patients at risk of bone localizations. 
Moreover, the accuracy of bone scanning can be improved 
with the addition of single-photon emission (SPECT)/CT 
owing to the greater contrast resolution of SPECT, to the 
elimination of summation artifacts characteristic of planar 
images, as well as for the ability to reduce false-positive 
findings through correlation with CT.37
XR has been historically used in metastatic breast cancer 
to study a limited bone anatomical region as a complement 
to BS and for settling equivocal findings (e.g., “suspicious” 
lesions or a single “hot spot”). However, metastatic lesions 
on XR may not appear for several months, as 30% to 75% 
of normal bone mineral content must be lost before lesions 
become visible. 
Finally, 18F-sodium fluoride positron emission tomo-
graphy/CT (NaF-PET/CT) provides very sensitive detec-
tion and visualization of breast cancer bone metastases. 
18F-sodium fluoride (18F-NaF) reflects the increased regional 
blood flow and osteoblastic bone reaction. In particular, 
greater activity of bone turnover determines greater blood 
flow and exchange surface for 18F-fluoride ion absorption 
and subsequent irreversible incorporation into the bone 
matrix as fluorapatite. In a recent study, sensitivity and 
specificity for NaF-PET were 91% and 91%, respectively, 
compared with 77% and 93% for CT. The integrated assess-
ment of NaF-PET/CT yielded a sensitivity of 98%, with a 
corresponding specificity of 93%.16 18F-NaF is characterized 
by an extremely high sensitivity rather than low specific-
ity for both sclerotic and lytic lesions; thanks to its better 
spatial resolution this tracer is even capable of capturing the 
increased mineral metabolism related to the thin reactive 
border that may surround a lytic lesion. In a recent study, 
Capitanio et al suggested that the extremely high sensitivity 
of 18F-NaF uptake could be advantageous in specific clinical 
settings (such as small CT-evident sclerotic lesions), pos-
sibly changing patient staging or management, particularly 
when performed in patients who would be candidates for 
regional therapy (i.e., surgery or radiotherapy), with the 
aim of excluding further occult metastases. In conclusion, 
patients could benefit from 18F-NaF PET when, in the pres-
ence of suspected biochemical or clinical disease relapse, 
other imaging tests give a negative result. Therefore, 18F-
NaF PET/CT is emerging as a “second-line” functional 
imaging tool, which may be of use in patients selected on 
the basis of their specific clinical history.38
MRI is more sensitive in detecting soft tissue metasta-
ses, particularly in the brain and the liver. Studies have also 
established the diagnostic advantage of whole-body MRI 
(sensitivity of 92% and specificity of 90%) over BS (sen-
sitivity of 83% and specificity of 80%). Furthermore, MRI 
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can provide detailed images of the bone and bone marrow, 
which physiologically show a high-intensity signal on T1 
imaging, whereas metastases appear as areas of reduced 
signal, reflecting the replacement of fat in the marrow by the 
tumor. Additionally, bone marrow signal can be canceled by 
techniques that saturate the intrinsic fat content thus high-
lighting small lesions with specific sequences like short-tau 
inversion recovery, T2 weighted fat-saturated turbo spin echo 
(TSE) and diffusion-weighted sequences.39,40 Even if MRI is 
better than CT for detecting bone marrow lesions or spinal 
cord and nerve root compression, CT may be preferable for 
assessing destruction of bone structure in axial bone local-
izations. In fact, cortical bone does not produce a signal and 
appears black both on T1 and T2-weighted sequences.16,31,35
Review of the diagnostic accuracy of 
18F-fluorodeoxyglucose (FDG) PET/
CT for breast cancer recurrence 
compared with other diagnostic 
methods
In the last decades, in addition to conventional imaging 
techniques (CT, BS) and MRI, 18F-FDG PET/CThas shown 
a relevant impact in the detection and management of breast 
cancer recurrence, especially in selected groups of patients 
presenting doubtful findings. According to European Society 
for Medical Oncology (ESMO) clinical guidelines on breast 
cancer, detection of early local recurrences and identification 
of contralateral relapses are the principal aims in the surveil-
lance in these patients.41 However, the same guidelines state 
that no conclusive demonstration exists that imaging tests, 
including FDG PET/CT, can produce a survival benefit in 
asymptomatic patients.41 By contrast, ESMO guidelines 
on locally recurrent and metastatic breast cancer as well as 
NCCN guidelines suggest that FDG PET/CT can be useful 
for identifying the site of relapse when traditional imag-
ing methods are equivocal or conflicting. Moreover, this 
imaging modality can improve the identification of isolated 
loco-regional relapse as well as isolated metastatic lesions, 
that is, a situation where patients may benefit from a more 
aggressive multidisciplinary approach.42,43 Similarly, 18F-FDG 
PET/CT has been proposed in the case of increasing tumor 
markers and inconclusive conventional imaging. In all these 
settings, FDG PET/CT allows meeting of  this target owing to 
its high sensitivity (77%–90%) and specificity (69%–80%).44 
These rates are even higher in patients with increased serum 
CA15.3 levels (cut-off 31.3 U/mL) and a radiologic suspicion 
of recurrence. For those, a sensitivity of 92.7% is reported.44
FDG PET uptake in breast cancer lesions is influenced by 
several factors. In fact, the aggressiveness of breast cancer, 
based on histological features, is directly related to glucose 
metabolism. Similarly, invasive ductal carcinoma type, triple 
negative receptorial pattern, elevated Ki-67 and undifferenti-
ated histopathology (G3) all correlated with a higher 18F-FDG 
uptake at PET/CT.45 By contrast, false-negative PET/CT 
results can occur due to low FDG uptake in some conditions, 
such as ILC, ongoing endocrine therapy, and small highly 
sclerotic skeletal lesions with low rate of actively replicat-
ing cells. Finally, the relatively low specificity of PET/CT in 
patients with high levels of tumor markers might be related to 
bone degenerative disease, lung inflammation, reconstruction 
artifacts, in particular in patients with breast expanders, as 
well as to other inflammations that are the common cause of 
false-positive findings with FDG.46
Increasing tumor markers
In patients with suspected recurrent disease because of 
increased CA15.3, carcinoembryonic antigen (CEA) or can-
cer antigen 125 (CA125), FDG PET/CT has demonstrated 
a high positive predictive value (PPV) (97%) and accuracy 
(83%–86%).46–48 In fact, compared with other methods (CT 
or MRI), FDG PET/CT shows a higher accuracy in the differ-
ential diagnosis between loco-regional recurrence and post-
treatment scar or inflammation phenomena.49–51 On the other 
hand, the negative predictive value (NPV) is <60%.50 One 
possible explanation is that lesions with a diameter <5 mm 
are below the spatial resolution of PET/CT. Nevertheless, 
FDG PET/CT shows an improved NPV in the early evalua-
tion of HR+ patients during therapy, allowing identification 
of the non-responders, characterized by a poorer prognosis.52
Suárez et al reported that CA15.3 blood levels >60 U/mL 
were always associated with positive PET, while CA15.3 
blood levels <50 U/mL were always associated with a nega-
tive one.53 Similarly, Liu et al showed that the diagnostic 
sensitivity and accuracy of FDG PET in patients with 
suspected recurrent breast cancer and asymptomatically 
elevated tumor markers, were 96% and 90%.54 On the other 
side, a systematic review by Evangelista et al showed that 
PET/CT allows 83% accuracy in the assessment of the 
site and extent of the recurring disease, irrespective of the 
value of CA15.3 and CT findings. However, no single cut-
off value yielding an acceptable sensitivity and specificity 
has been so far identified.46 Figure 1 shows a representative 
example of a breast cancer patient submitted to FDG PET 
because of increasing tumor markers in the presence of a 
negative CT scan.





Restaging in inconclusive cases 
and metastatic patients who are 
candidates for surgery
Accurate restaging is of pivotal importance in patients with 
suspicion of loco-regional cancer recurrence, as a limited 
relapse extent implies the possibility of a salvage surgery. 
The clinical management and prognosis of these patients 
are, in fact, mainly based on the extent of the loco-regional 
recurrence and on the absence of distant metastases.49 In this 
setting, some authors demonstrated that FDG PET/CT had 
a substantial impact on clinical management in 51%–69% 
of patients.48,55,56
In a study by Cochet et al56 conventional imaging (CI) 
findings were indicative of relapse in the majority of patients 
(54/66); however, 18F-FDG PET/CT downstaged 12 patients, 
providing a better negative predictive value when compared 
with CI alone. These findings suggest that FDG PET/CT 
is not only effective for relapse detection in patients with 
negative conventional imaging findings, but also may provide 
a better lesions’ characterization in patients with a strong 
suspicion of relapse. In this clinical scenario, several studies 
documented that PET is superior to chest radiography for the 
detection of pulmonary metastases.57,58 Integration of PET 
with CT could further increase the sensitivity in the detection 
of recurrent disease in the chest compared with radiography. 
PET efficiently detects supra-centimetric disease-related 
pulmonary nodules and liver lesions; however, because of 
the partial-volume effect and respiratory movements, PET 
lacks in sensitivity for smaller lesions. In this context, as CT 
might be more to detect smaller lesions, also ones within 
the liver, hybrid imaging with FDG PET and full diagnostic 
contrast-enhanced CT has been proposed and might be of 
use in selected cases.59 However, it has to be underlined that 
MRI has been demonstrated to be superior to both CT and 
FDG PET for the detection of small liver lesions with the 
use of hepatic-specific MR contrast agents.60
Finally, restaging of breast cancer patients at high risk 
for liver metastasis might be a potential indication for PET/
MRI. However, only preliminary experience is available and 
studies in larger number of patients are needed.16
Distant metastases from breast cancer most frequently 
occur in the skeleton61,62 and, on the basis of radiographic 
appearance, they can be classified as osteoblastic, osteolytic 
or mixed pattern.63 The pathological osteoblastic activity may 
be indistinguishable on imaging from reactive and reparative 
activity after a successful treatment of bone metastases. The 
uptake of 18F-FDG in viable bone metastases is assumed to 
be mainly within breast cancer tumor cells rather than in 
A B
C ED
Figure 1 Breast cancer patient with rising tumor marker (cancer antigen 15.3) and negative CT scan.
Notes: FDG-PET highlights an 11 mm lymph node with moderate FDG uptake. The presence of disease relapse within this lymph node was confirmed by means of 
ultrasound-guided biopsy. Three-section imaging (A: PET; B: three-slices fused imaging); transaxial section (C: fused imaging; D: PET; E: CT).
Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
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osteoblasts; therefore, it can be considered as a tumor-specific 
tracer rather than a direct index of alteration of bone micro-
environment. Several authors have reported lower sensitivity 
for 18F-FDG PET in osteoblastic lesions than in osteolytic 
ones.64–73 Different factors may contribute to the differences 
in 18F-FDG avidity between osteoblastic and osteolytic metas-
tases. Histologic subtype could also be an important factor: 
ILC has been reported to show osteoblastic metastases with 
poor 18F-FDG uptake more frequently than invasive ductal 
carcinoma.66 Previous treatments are also relevant, as many 
18F-FDG-negative skeletal metastases may appear sclerotic 
as a consequence of previous systemic therapy, making 
tumor cells nonviable, even though ongoing reparative 
osteoblastic activity, as seen with BS or 18F-NaF PET, may 
persist.67 Figure 2 shows some representative examples of 
bone metastasis from breast cancer patients positive to either 
CT or FDG PET scan or to both examinations.
In a retrospective study, Tateishi et al highlighted the 
importance of standardized uptake value (SUV) as a predictor 
of disease progression, although both a change in FDG uptake 
and increased bone sclerosis on CT images predicted the time 
to progression.68 Therefore, FDG PET can improve the speci-
ficity of the bone metastases treatment response assessment. 
However, with respect to CI, 18F-FDG PET/CT may be able 
to tell the response or non-response to systemic therapy with 
more accuracy and at an earlier time point, changing the clini-
cal management of breast cancer patients.69 For the detection 
of skeletal metastases and staging of cancer, 18F-FDG PET 
or PET/CT has shown higher sensitivity and specificity than 
BS in many studies70,71 and meta-analyses.54,72,73 Benefits in 
specificity can derive from the lower numbers of false-positive 
uptakes of 18F-FDG with respect to the bone-seeking tracers. 
The improvement in sensitivity over bone scan may be also 
due to the ability of PET/CT imaging to detect metastatic 
tumor cells within bone marrow before there is a sufficient 
osteoblastic reaction to permit the detection by bone-specific 
tracers. However, utility of 18F-FDG PET/CT can be limited 
in the case of small bone lesions, showing no visible morpho-
logic changes in the co-registered CT images or absence of 
significant tracer uptake, in particular for lesions whose size 
is <2 times the spatial resolution of the scanner (4–6 mm).
Feasibility and patient outcomes
Compared with other imaging modalities, 18F-FDG PET/
CT allows achieving the evaluation of the whole body with 
a single examination, avoiding delays in disease restaging. 
Although low-dose CT is principally used for attenuation cor-
rection, it also allows an anatomical localization of glucose 
Figure 2 Comparison between PET and CT in different types of bone lesions.
Notes: A–C: vertebral lesion with high FDG uptake in the absence of structural lesion on CT (metastasis in the bone marrow); D–F: CT sclerotic lesion in the right iliac bone 
with no concentration of FDG (likely a lesion with low cellularity); G–I: mixed bone lesion in the right sacroiliac bone on CT images markedly positive on the FDG PET scan.









avid areas, adding the morphological data to the metabolic 
results. FDG PET/CT is a non-invasive examination of rela-
tively short duration and not requiring special preparation, 
other than a 6-hour fasting. Furthermore, the impact of FDG 
PET/CT restaging on patients’ management is noteworthy, 
as it has been reported to modify the treatment decisions in 
a not negligible number of cases.47,48,74 In this framework, 
it has to be underlined that although guidelines do not rec-
ommend FDG PET for the surveillance of asymptomatic 
patients with non-metastatic breast cancer, FDG PET/CT is 
commonly required by clinicians in routine clinical practice. 
Accordingly, there is an urgent need for accurate economic 
evaluations of breast cancer management so as to ensure 
efficient use of healthcare resources as well as to avoid the 
use of third level examination such as FDG PET when impact 
on patients’ outcome is not proven.75
FDG PET can add, to the restaging capabilities, a sig-
nificant prognostic relevance, as the survival of patients who 
develop an isolated loco-regional recurrence differs signifi-
cantly from patients who have distant relapse. Consequently, 
determination of both the locations and the extent of the 
recurrent disease is essential to guide therapeutic decisions 
and estimate prognosis. Some authors have suggested that 
FDG PET/CT can have a significant impact on the therapeu-
tic management; however, information concerning its utility 
for a long-term prognostic stratification, when compared 
with CI, is limited.48 In particular, there is no consensus 
about the best PET-derived parameters to predict patients’ 
prognosis and/or survival.76 First published studies were 
focused on the prognostic value of SUV
max
, without testing 
other PET parameters.76 More recently, other PET-derived 
parameters such as metabolic tumor volume (MTV) and 
total lesion glycolysis  have demonstrated to potentially 
improve risk stratification, in this specific subtype of breast 
cancer patients.77–80
Finally, tumor heterogeneity as measured by means of 
textural analysis has also emerged as a potential prognostic 
factor in BC patients.81,82 However, a multivariate analyses 
performed by Groheux et al79 demonstrated that MTV, but 
not textural analysis of PET images, was an independent 
prognostic indicator in ER+/HER2- breast cancer patients, 
before neoadjuvant chemotherapy. As a matter of fact, there 
is an increasing need to characterize biological processes 
for early prediction and monitoring of response to therapy 
in breast cancer patients and 18F-FDG PET has been tested 
and compared with other PET probes also in this setting.83
Although comparative studies using multiple FDG probes 
are relatively scarce and most frequently performed in animal 
models, available data suggest that other molecular imaging 
tools, such as 18F-fluoroestradiol PET/CT, can provide a 
more precise early prediction of tumor response, especially 
to endocrine therapy in ER+ breast cancer.83
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability
Quality of life, evaluated in quality-adjusted life years 
(QALY)84 represents one of the main hallmarks of patient 
care. This approach implies that the benefits of any medical 
procedure should always be considered in light of the patients’ 
well-being.85 This aspect is of particular importance in breast 
cancer survivors, given the high prevalence of this disease, 
the elevated 5-year survival rate and the importance of early 
detection of any disease recurrence.86
The advent of PET and PET/CT was able to bring about 
remarkable improvements, as the use of these techniques 
afforded higher QALY and decreased the error rate, with 
respect to conventional imaging.87 It does, however, require 
higher costs and for this reason is not accessible to all patients 
in all countries.
Moreover, another important aspect to consider is 
whether the execution of additional tests can increase the 
anxiety levels in these patients. Fear of tumor relapse is a 
well-recognized cause of decreased quality of life;88 patients 
affected by fear of relapse tend to associate the number of 
visits/imaging sessions with improved outcome. A study by 
Hong et al indicated that virtually all patients demand the 
execution of tumor markers and PET/CT, regardless of their 
initial staging and risk class.84 Actually, execution of repeated 
medical imaging might be a double-edged sword: on one 
side, it could reassure the patient on the absence of disease; 
on the other hand, it can increase, or at least perpetuate, the 
patient´s anxiety before the examinations and in the case of 
false-positive results.89
These considerations are also valid for PET/CT, which 
is an expensive image modality that should not be used 
for mere patient “reassurance”.90 However, this image 
modality is also characterized by an improved specificity 
with respect to conventional imaging.91 In light of this, the 
accurate selection of patients who could actually benefit 
from the execution of this imaging approach appears to be 
of pivotal importance. On the other hand, patients in whom 
PET/CT surveillance is not indicated should be reassured 
about their condition and instructed on the rationale of the 
follow-up modality, so as to promote their psychological 
well-being.88
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Conclusions
In conclusion, while there are no conclusive data indicating 
that FDG PET/CT produces a survival benefit in asymp-
tomatic patients, FDG PET/CT can be useful in identifying 
the site of relapse when CI is equivocal and confirming 
isolated loco-regional relapse or isolated metastatic lesions 
in patients who are candidates for surgery or loco-regional 
treatment. In all these settings, FDG PET/CT has demon-
strated high sensitivity (77%–90%) and specificity (69%–
80%) and has a substantial impact on clinical management 
in a relevant number of patients. By contrast, information 
concerning its utility for long-term prognostic stratification, 
when compared with CI, is limited and further studies will 
aid in better defining the role of PET during breast cancer 
follow-up. In the meantime, it appears of utmost importance 
to always discuss and evaluate on a patient-by-patient basis 
the benefits and risks of a PET-based follow-up, in terms 
of outcome as well as psychological well-being and quality 
of life.
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